Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 2
1976 1
1977 1
1978 4
1979 2
1980 2
1981 5
1982 3
1983 4
1984 1
1985 2
1986 3
1987 4
1988 2
1989 1
1990 2
1992 3
1993 3
1994 3
1998 2
1999 1
2000 2
2001 2
2003 6
2004 10
2005 7
2006 6
2007 5
2008 6
2009 8
2010 4
2011 11
2012 14
2013 14
2014 17
2015 8
2016 1
2017 2
2018 5
2019 5
2020 2
2021 2
2022 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Results by year

Filters applied: . Clear all
Page 1
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS; SPIRIT H2H study group. Mease PJ, et al. Among authors: krishnan e. Ann Rheum Dis. 2020 Jan;79(1):123-131. doi: 10.1136/annrheumdis-2019-215386. Epub 2019 Sep 28. Ann Rheum Dis. 2020. PMID: 31563894 Free PMC article. Clinical Trial.
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group. van der Heijde D, et al. Among authors: krishnan e. Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22. Lancet. 2018. PMID: 30360964 Clinical Trial.
Gout and the heart.
Bhole V, Krishnan E. Bhole V, et al. Among authors: krishnan e. Rheum Dis Clin North Am. 2014 Feb;40(1):125-43. doi: 10.1016/j.rdc.2013.10.004. Rheum Dis Clin North Am. 2014. PMID: 24268013 Review.
Filipino gout: a review.
Prasad P, Krishnan E. Prasad P, et al. Among authors: krishnan e. Arthritis Care Res (Hoboken). 2014 Mar;66(3):337-43. doi: 10.1002/acr.22118. Arthritis Care Res (Hoboken). 2014. PMID: 23983155 Free article. Review. No abstract available.
Systemic sclerosis 2011.
Chung L, Distler O, Hummers L, Krishnan E, Steen V. Chung L, et al. Among authors: krishnan e. Int J Rheumatol. 2011;2011:308231. doi: 10.1155/2011/308231. Epub 2012 Apr 9. Int J Rheumatol. 2011. PMID: 22577388 Free PMC article. No abstract available.
Hyperuricaemia--where nephrology meets rheumatology.
Avram Z, Krishnan E. Avram Z, et al. Among authors: krishnan e. Rheumatology (Oxford). 2008 Jul;47(7):960-4. doi: 10.1093/rheumatology/ken070. Epub 2008 Apr 27. Rheumatology (Oxford). 2008. PMID: 18443007 Review.
Renal cell carcinoma--angioinfarction.
Mebust WK, Weigel JW, Lee KR, Cox GG, Jewell WR, Krishnan EC. Mebust WK, et al. Among authors: krishnan ec. J Urol. 1984 Feb;131(2):231-5. doi: 10.1016/s0022-5347(17)50320-1. J Urol. 1984. PMID: 6199518
182 results